Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
Saved in:
| Title: | Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. |
|---|---|
| Authors: | Lebwohl MG; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Stein Gold L; Henry Ford Hospital, Detroit, MI, USA., Papp K; Probity Medical Research and K. Papp Clinical Research, Waterloo, ON, Canada., Han G; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Pariser DM; Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA., Lin T; Ortho Dermatologics†, Bridgewater, NJ, USA., Harris S; Bausch Health US, LLC†, Bridgewater, NJ, USA., Jacobson A; Ortho Dermatologics†, Bridgewater, NJ, USA. |
| Source: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 May; Vol. 35 (5), pp. 1152-1160. Date of Electronic Publication: 2021 Feb 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1468-3083 |
|---|---|
| DOI: | 10.1111/jdv.17113 |
